CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy
Clustered regularly interspaced short palindromic repeat-associated protein Cas9 (CRISPR/Cas9) technology is at the forefront of cancer immunotherapy innovation, offering precise and personalized treatment strategies. In this review, we discuss CRISPR/Cas9’s ability to precisely edit the genome, its...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-03-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/16/3/346 |
| _version_ | 1797239658564812800 |
|---|---|
| author | Hyeseon Park Yoo Kyung Kang Gayong Shim |
| author_facet | Hyeseon Park Yoo Kyung Kang Gayong Shim |
| author_sort | Hyeseon Park |
| collection | DOAJ |
| description | Clustered regularly interspaced short palindromic repeat-associated protein Cas9 (CRISPR/Cas9) technology is at the forefront of cancer immunotherapy innovation, offering precise and personalized treatment strategies. In this review, we discuss CRISPR/Cas9’s ability to precisely edit the genome, its impact on immune checkpoint control, and its application in immune cell engineering, where it surpasses traditional gene editing techniques. Originally inspired by bacterial defense mechanisms, this technology has made great strides in cancer immunotherapy as a mechanism to specifically target the PD-1/PD-L1 pathway in immune checkpoint blockades. In addition, CRISPR/Cas9 plays an important role in cancer treatment by facilitating genetic modifications to enhance the properties of adoptive cell therapy, optimizing the therapeutic potential of this approach. This review provides an overview of the development of CRISPR/Cas9, its important role in immune checkpoint control, applications in immune cell engineering, and the current status of clinical trials. However, safety concerns related to off-target effects and unintended mutations require continued research and caution. Continued advances in CRISPR technology hold the promise of revolutionizing the cancer treatment paradigm, providing personalized and effective therapies for patients with various types of cancer. |
| first_indexed | 2024-04-24T17:55:02Z |
| format | Article |
| id | doaj.art-617bf92e50d248239f50cd00f8d6a0de |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-04-24T17:55:02Z |
| publishDate | 2024-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-617bf92e50d248239f50cd00f8d6a0de2024-03-27T13:59:40ZengMDPI AGPharmaceutics1999-49232024-03-0116334610.3390/pharmaceutics16030346CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell TherapyHyeseon Park0Yoo Kyung Kang1Gayong Shim2School of Systems Biomedical Science and Integrative Institute of Basic Sciences, Soongsil University, Seoul 06978, Republic of KoreaCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju 52828, Republic of KoreaSchool of Systems Biomedical Science and Integrative Institute of Basic Sciences, Soongsil University, Seoul 06978, Republic of KoreaClustered regularly interspaced short palindromic repeat-associated protein Cas9 (CRISPR/Cas9) technology is at the forefront of cancer immunotherapy innovation, offering precise and personalized treatment strategies. In this review, we discuss CRISPR/Cas9’s ability to precisely edit the genome, its impact on immune checkpoint control, and its application in immune cell engineering, where it surpasses traditional gene editing techniques. Originally inspired by bacterial defense mechanisms, this technology has made great strides in cancer immunotherapy as a mechanism to specifically target the PD-1/PD-L1 pathway in immune checkpoint blockades. In addition, CRISPR/Cas9 plays an important role in cancer treatment by facilitating genetic modifications to enhance the properties of adoptive cell therapy, optimizing the therapeutic potential of this approach. This review provides an overview of the development of CRISPR/Cas9, its important role in immune checkpoint control, applications in immune cell engineering, and the current status of clinical trials. However, safety concerns related to off-target effects and unintended mutations require continued research and caution. Continued advances in CRISPR technology hold the promise of revolutionizing the cancer treatment paradigm, providing personalized and effective therapies for patients with various types of cancer.https://www.mdpi.com/1999-4923/16/3/346CRISPR/Cas9cancer immunotherapyimmune checkpointT-cell therapy |
| spellingShingle | Hyeseon Park Yoo Kyung Kang Gayong Shim CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy Pharmaceutics CRISPR/Cas9 cancer immunotherapy immune checkpoint T-cell therapy |
| title | CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy |
| title_full | CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy |
| title_fullStr | CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy |
| title_full_unstemmed | CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy |
| title_short | CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy |
| title_sort | crispr cas9 mediated customizing strategies for adoptive t cell therapy |
| topic | CRISPR/Cas9 cancer immunotherapy immune checkpoint T-cell therapy |
| url | https://www.mdpi.com/1999-4923/16/3/346 |
| work_keys_str_mv | AT hyeseonpark crisprcas9mediatedcustomizingstrategiesforadoptivetcelltherapy AT yookyungkang crisprcas9mediatedcustomizingstrategiesforadoptivetcelltherapy AT gayongshim crisprcas9mediatedcustomizingstrategiesforadoptivetcelltherapy |